A 2024 study showed while the overall lifetime prevalence of AAS use among adult women globally is 4% (up from 1.6% in 2014), the rate is higher in specific fitness communities ...

Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who ...

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity ...

Doctors break down the difference between Wegovy’s GLP-1 injections and pills, plus how to decide which is right for you.

A new Wegovy pill is now available nationwide, giving adults a daily tablet option instead of weekly shots for weight loss ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.

New options for testing and treating some of the most common sexually transmitted diseases are becoming available.

The FDA has approved Zycubo (copper histidinate) injection as the first and only treatment of Menkes disease in pediatric ...

Novo Nordisk anticipates oral weight-loss drugs will capture one-third or more of the GLP-1 market by 2030, driven by ...